[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2003095427A1 - Compose a noyau spiranique - Google Patents

Compose a noyau spiranique Download PDF

Info

Publication number
WO2003095427A1
WO2003095427A1 PCT/JP2003/005812 JP0305812W WO03095427A1 WO 2003095427 A1 WO2003095427 A1 WO 2003095427A1 JP 0305812 W JP0305812 W JP 0305812W WO 03095427 A1 WO03095427 A1 WO 03095427A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
spiro
ring compound
hydrogen
formulae
Prior art date
Application number
PCT/JP2003/005812
Other languages
English (en)
Japanese (ja)
Inventor
Shiuji Saito
Hiroki Umemiya
Yoichirou Suga
Masakazu Sato
Naoya Kawashima
Original Assignee
Taisho Pharmaceutical Co.,Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co.,Ltd. filed Critical Taisho Pharmaceutical Co.,Ltd.
Priority to JP2004508514A priority Critical patent/JPWO2003095427A1/ja
Priority to AU2003235912A priority patent/AU2003235912A1/en
Publication of WO2003095427A1 publication Critical patent/WO2003095427A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé à noyau spiranique représenté par la formule (1) dans laquelle le groupe représenté par la formule (2) est représenté par une quelconque des formules (3) à (7), dans lesquelles B représente, par exemple, un noyau de benzène éventuellement substitué par un ou plusieurs groupes de type identique ou différent sélectionnés dans le groupe comprenant halogéno, alkyle C1-5, etc.; R1 et R2 sont identiques ou différents et chacun représente hydrogène, alkyle C1-5, etc.; R3 représente, par exemple, hydrogène, alkyle C1-5, acyle C1-6 éventuellement substitué par alcoxy C1-5, etc.; R4 représente hydrogène ou alkyle C1-5; -X1-X2- représente une quelconque des formules (8) à (12) (dans lesquelles R5 représente hydrogène, cycloalkyle C3-6, etc.); W représente cyclooctyle, alkyle C3-6 substitué par cyclooctyle ou alkyle C1-3 substitué par 1-hydroxycyclooctyle; et m est un entier de 0 à 3. L'invention concerne également un sel acceptable d'un point de vue pharmaceutique du composé à noyau spiranique.
PCT/JP2003/005812 2002-05-10 2003-05-09 Compose a noyau spiranique WO2003095427A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2004508514A JPWO2003095427A1 (ja) 2002-05-10 2003-05-09 スピロ環化合物
AU2003235912A AU2003235912A1 (en) 2002-05-10 2003-05-09 Spiro-ring compound

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002-135988 2002-05-10
JP2002135988 2002-05-10
JP2002214248 2002-07-23
JP2002-214248 2002-07-23

Publications (1)

Publication Number Publication Date
WO2003095427A1 true WO2003095427A1 (fr) 2003-11-20

Family

ID=29422399

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/005812 WO2003095427A1 (fr) 2002-05-10 2003-05-09 Compose a noyau spiranique

Country Status (3)

Country Link
JP (1) JPWO2003095427A1 (fr)
AU (1) AU2003235912A1 (fr)
WO (1) WO2003095427A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006058303A3 (fr) * 2004-11-29 2006-12-21 Vertex Pharma Modulateurs des recepteurs muscariniques
US7879834B2 (en) 2004-08-19 2011-02-01 Vertex Pharmaceuticals Incorporated Spiroindoline modulators of muscarinic receptors
WO2011060217A1 (fr) 2009-11-16 2011-05-19 Eli Lilly And Company Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1
WO2011060035A1 (fr) 2009-11-16 2011-05-19 Eli Lilly And Company Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1
US8263605B2 (en) 2006-02-22 2012-09-11 Vertex Pharmaceutical Incorporated Modulators of muscarinic receptors
US8304423B2 (en) 2006-02-22 2012-11-06 Vertex Pharmaceutical Incorporated Modulators of muscarinic receptors
US8367691B2 (en) 2004-08-19 2013-02-05 Vertex Pharmaceutical Incorporated Modulators of muscarinic receptors
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
US8828996B2 (en) 2011-03-14 2014-09-09 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
US8916565B2 (en) 2011-02-02 2014-12-23 Vertex Pharmaceuticals Incorporated Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
JP2018058874A (ja) * 2010-10-18 2018-04-12 セレニス セラピューティクス ホールディング エスアー コレステロールモビリゼーションに有用な化合物、組成物及び方法
US10385070B2 (en) 2011-02-18 2019-08-20 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
JP2022036285A (ja) * 2015-12-02 2022-03-04 アストライア セラピューティクス， エルエルシー ピペリジニルノシセプチン受容体化合物
US11827617B2 (en) 2015-12-02 2023-11-28 Astraea Therapeutics, Llc Piperidinyl nociceptin receptor compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55143980A (en) * 1979-04-27 1980-11-10 Dai Ichi Seiyaku Co Ltd Anti-allergic preparation
EP0431943A2 (fr) * 1989-12-08 1991-06-12 Merck & Co. Inc. Spirocycles azotés
WO2000034280A1 (fr) * 1998-12-09 2000-06-15 Banyu Pharmaceutical Co., Ltd. Composes heterocycliques de 4-oxo-imidazolidine-2-spiro-azote

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55143980A (en) * 1979-04-27 1980-11-10 Dai Ichi Seiyaku Co Ltd Anti-allergic preparation
EP0431943A2 (fr) * 1989-12-08 1991-06-12 Merck & Co. Inc. Spirocycles azotés
WO2000034280A1 (fr) * 1998-12-09 2000-06-15 Banyu Pharmaceutical Co., Ltd. Composes heterocycliques de 4-oxo-imidazolidine-2-spiro-azote

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879834B2 (en) 2004-08-19 2011-02-01 Vertex Pharmaceuticals Incorporated Spiroindoline modulators of muscarinic receptors
US8497295B2 (en) 2004-08-19 2013-07-30 Vertex Pharmaceuticals Incorporated Spiroindoline modulators of muscarinic receptors
US8367691B2 (en) 2004-08-19 2013-02-05 Vertex Pharmaceutical Incorporated Modulators of muscarinic receptors
US8258148B2 (en) 2004-08-19 2012-09-04 Vertex Pharmaceutical Incorporated Spiroindoline modulators of muscarinic receptors
JP2008521825A (ja) * 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
WO2006058303A3 (fr) * 2004-11-29 2006-12-21 Vertex Pharma Modulateurs des recepteurs muscariniques
US8304423B2 (en) 2006-02-22 2012-11-06 Vertex Pharmaceutical Incorporated Modulators of muscarinic receptors
US8263605B2 (en) 2006-02-22 2012-09-11 Vertex Pharmaceutical Incorporated Modulators of muscarinic receptors
US8232289B2 (en) 2009-11-16 2012-07-31 Eli Lilly And Company Spiropiperidine compounds as ORL-1 receptor antagonists
WO2011060217A1 (fr) 2009-11-16 2011-05-19 Eli Lilly And Company Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1
WO2011060035A1 (fr) 2009-11-16 2011-05-19 Eli Lilly And Company Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
JP2018058874A (ja) * 2010-10-18 2018-04-12 セレニス セラピューティクス ホールディング エスアー コレステロールモビリゼーションに有用な化合物、組成物及び方法
US10220040B2 (en) 2010-10-18 2019-03-05 Cerenis Therapeutics Holding Sa Compounds, compositions and methods useful for cholesterol mobilization
US8916565B2 (en) 2011-02-02 2014-12-23 Vertex Pharmaceuticals Incorporated Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
US9511067B2 (en) 2011-02-02 2016-12-06 Vertex Pharmaceuticals Incorporated Substituted spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]s as modulators of ion channels
US10385070B2 (en) 2011-02-18 2019-08-20 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
US9181273B2 (en) 2011-03-14 2015-11-10 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
US8828996B2 (en) 2011-03-14 2014-09-09 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
JP2022036285A (ja) * 2015-12-02 2022-03-04 アストライア セラピューティクス， エルエルシー ピペリジニルノシセプチン受容体化合物
US11827617B2 (en) 2015-12-02 2023-11-28 Astraea Therapeutics, Llc Piperidinyl nociceptin receptor compounds
USRE49825E1 (en) 2015-12-02 2024-02-06 Astraea Therapeutics, Llc Piperidinyl nociceptin receptor compounds
JP7472175B2 (ja) 2015-12-02 2024-04-22 アストライア セラピューティクス， エルエルシー ピペリジニルノシセプチン受容体化合物

Also Published As

Publication number Publication date
AU2003235912A1 (en) 2003-11-11
JPWO2003095427A1 (ja) 2005-09-15

Similar Documents

Publication Publication Date Title
WO2003095427A1 (fr) Compose a noyau spiranique
TW351715B (en) Benzoyl derivatives
WO2005061458A3 (fr) Inhibiteurs de la phosphodiesterase 4, notamment analogues de diarylamines n-substituees
EP1679069A4 (fr) Nouveau derive de piperidine
WO2002081428A1 (fr) Compose de benzene et sel de ce compose
EP1642880A4 (fr) Inhibiteur de proteines de la famille hsp90
WO2004103977A3 (fr) Procede de preparation de derives de pyrimidine
WO2002014439A3 (fr) Methode de production de revetements utilisant des photoamorceurs en siloxane
DE602004018878D1 (de) Cyaninverbindung, optisches Aufzeichnungsmaterial und optisches Aufzeichnungmedium
EA200100310A1 (ru) Кислородсодержащие гетероциклические соединения
EP1295867A4 (fr) Compose biphenyle
WO2005020293A3 (fr) Films fins hautement conducteurs et transparents constitues de nouveaux derives fluores de 3,4-ethylenedioxythiophene
ATE268330T1 (de) Azaidole mit serotonin rezeptor affinität
WO2003078390A8 (fr) Compose phenolique et materiau d'enregistrement contenant ce dernier
MXPA04002569A (es) H6,7-dihidro-5h-pirazolo[1,2-a]pirazol-1-onas espirociclicas que controlan citocinas inflamatorias.
EP0926146A4 (fr) Composes de chromene
WO2002000638A3 (fr) Nouveaux phthalides substitues, leur procede de preparation et compositions pharmaceutiques les contenant
AU2001269540A1 (en) Serotonin reuptake inhibitors
EP1306369A4 (fr) Nouveaux composes sulfures et composes intermoleculaires renfermant lesdits composes comme composant
EP1535920A4 (fr) Methode de preparation de derives de 1,3-benzodioxole-2-spiro-cycloalcane
EP1493765A4 (fr) Polymeres organiques presentant a leurs extremites des groupes de silicium contenant un groupe epoxy et/ou oxetanyl, et procede de production de ces polymeres
EP1424326A4 (fr) Composes polycycliques fusionnes
DK0601191T3 (da) Hidtil ukendt tetracyklisk forbindelse
NO20031046L (no) Fremgangsmåte for fremstilling av en substituert imidazopyridinforbindelse
WO2004099130A3 (fr) Inhibiteur de cox

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004508514

Country of ref document: JP

122 Ep: pct application non-entry in european phase